Bulk Manufacturer of Controlled Substances Application: Research Triangle Institute, 37251-37252 [2024-09783]
Download as PDF
<![CDATA[
37251
Federal Register / Vol. 89, No. 88 / Monday, May 6, 2024 / Notices
Controlled substance
Drug code
ddrumheller on DSK120RN23PROD with NOTICES1
Nabilone ...............................................................................................................................................................................
1-Phenylcyclohexylamine ....................................................................................................................................................
Phencyclidine .......................................................................................................................................................................
ANPP (4-Anilino-N-phenethyl-4-piperidine) .........................................................................................................................
Phenylacetone .....................................................................................................................................................................
1-Piperidinocyclohexanecarbonitrile ....................................................................................................................................
Alphaprodine ........................................................................................................................................................................
Anileridine ............................................................................................................................................................................
Cocaine ................................................................................................................................................................................
Codeine ...............................................................................................................................................................................
Etorphine HCl ......................................................................................................................................................................
Dihydrocodeine ....................................................................................................................................................................
Oxycodone ...........................................................................................................................................................................
Hydromorphone ...................................................................................................................................................................
Diphenoxylate ......................................................................................................................................................................
Ecgonine ..............................................................................................................................................................................
Ethylmorphine ......................................................................................................................................................................
Hydrocodone .......................................................................................................................................................................
Levomethorphan ..................................................................................................................................................................
Levorphanol .........................................................................................................................................................................
Isomethadone ......................................................................................................................................................................
Meperidine ...........................................................................................................................................................................
Meperidine-intermediate-A ..................................................................................................................................................
Meperidine intermediate-B ..................................................................................................................................................
Meperidine intermediate-C ..................................................................................................................................................
Metazocine ..........................................................................................................................................................................
Methadone ...........................................................................................................................................................................
Methadone intermediate ......................................................................................................................................................
Metopon ...............................................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) ..................................................................................................................
Morphine ..............................................................................................................................................................................
Oripavine .............................................................................................................................................................................
Thebaine ..............................................................................................................................................................................
Dihydroetorphine .................................................................................................................................................................
Levo-alphacetylmethadol .....................................................................................................................................................
Oxymorphone ......................................................................................................................................................................
Noroxymorphone .................................................................................................................................................................
Phenazocine ........................................................................................................................................................................
Thiafentanil ..........................................................................................................................................................................
Piminodine ...........................................................................................................................................................................
Racemethorphan .................................................................................................................................................................
Racemorphan ......................................................................................................................................................................
Alfentanil ..............................................................................................................................................................................
Remifentanil .........................................................................................................................................................................
Sufentanil .............................................................................................................................................................................
Carfentanil ...........................................................................................................................................................................
Tapentadol ...........................................................................................................................................................................
Bezitramide ..........................................................................................................................................................................
Fentanyl ...............................................................................................................................................................................
Moramide-intermediate ........................................................................................................................................................
The company plans to import
analytical reference standards for
distribution to its customers for research
and analytics purposes. Placement of
these drug codes onto the company’s
registration does not translate into
automatic approval of subsequent
permit applications to import controlled
substances. No other activities for these
drug codes are authorized for this
registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or non-
VerDate Sep<11>2014
18:02 May 03, 2024
Jkt 262001
approved finished dosage forms for
commercial sale.
Marsha Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–09802 Filed 5–3–24; 8:45 am]
BILLING CODE P
PO 00000
7379
7460
7471
8333
8501
8603
9010
9020
9041
9050
9059
9120
9143
9150
9170
9180
9190
9193
9210
9220
9226
9230
9232
9233
9234
9240
9250
9254
9260
9273
9300
9330
9333
9334
9648
9652
9668
9715
9729
9730
9732
9733
9737
9739
9740
9743
9780
9800
9801
9802
Schedule
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1349]
Bulk Manufacturer of Controlled
Substances Application: Research
Triangle Institute
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Research Triangle Institute
has applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
SUMMARY:
Frm 00092
Fmt 4703
Sfmt 4703
E:\FR\FM\06MYN1.SGM
06MYN1
37252
Federal Register / Vol. 89, No. 88 / Monday, May 6, 2024 / Notices
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before July 5, 2024. Such persons
may also file a written request for a
hearing on the application on or before
July 5, 2024.
DATES:
The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
ADDRESSES:
In
accordance with 21 CFR 1301.33(a), this
is notice that on March 11, 2024,
Research Triangle Institute, 3040 East
Cornwallis Road, Hermann Building,
Room 106, Research Triangle Park,
North Carolina 27709–2194, applied to
be registered as a bulk manufacturer of
the following basic class(es) of
controlled substance(s):
SUPPLEMENTARY INFORMATION:
Drug
code
Controlled substance
Tetrahydrocannabinols ...
Schedule
I 7370 II
The company plans to bulk
manufacture the listed controlled
substance synthetically for distribution
to its customers for research and as
analytical reference standards. No other
activities for this drug code are
authorized for this registration.
Marsha Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–09783 Filed 5–3–24; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1359]
Importer of Controlled Substances
Application: Restek Corporation
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Restek Corporation has
applied to be registered as an importer
of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before June 5, 2024. Such persons
may also file a written request for a
SUMMARY:
hearing on the application on or before
June 5, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on March 5, 2024, Restek
Corporation, 110 Benner Circle,
Bellefonte, Pennsylvania 16823–8433,
applied to be registered as an importer
of the following basic class(es) of
controlled substance(s):
ddrumheller on DSK120RN23PROD with NOTICES1
Controlled substance
Drug code
Amineptine ...........................................................................................................................................................................
Mesocarb .............................................................................................................................................................................
3-Fluoro-N-methylcathinone (3–FMC) .................................................................................................................................
Cathinone ............................................................................................................................................................................
Methcathinone .....................................................................................................................................................................
4-Fluoro-N-methylcathinone (4–FMC) .................................................................................................................................
Para-Methoxymethamphetamine (PMMA), 1-(4–1245 I N methoxyphenyl)-N-methylpropan-2-amine ..............................
Pentedrone (a-methylaminovalerophenone) .......................................................................................................................
Mephedrone (4-Methyl-N-methylcathinone .........................................................................................................................
4-Methyl-N-ethylcathinone (4–MEC) ...................................................................................................................................
Naphyrone ...........................................................................................................................................................................
N-Ethylamphetamine ...........................................................................................................................................................
Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2- 1478 I N amine) ..........................................................................
N,N-Dimethylamphetamine ..................................................................................................................................................
Fenethylline .........................................................................................................................................................................
Aminorex ..............................................................................................................................................................................
4-Methylaminorex (cis isomer) ............................................................................................................................................
4,4′-Dimethylaminorex .........................................................................................................................................................
Gamma Hydroxybutyric Acid ...............................................................................................................................................
Methaqualone ......................................................................................................................................................................
Mecloqualone ......................................................................................................................................................................
JWH–250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole) ......................................................................................................
SR–18 (Also known as RCS–8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) ....................................................
ADB–FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) .................
5-Fluoro-UR–144 and XLR11 [1-(5-Fluoro-pentyl)1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone ....................
VerDate Sep<11>2014
18:02 May 03, 2024
Jkt 262001
PO 00000
Frm 00093
Fmt 4703
Sfmt 4703
E:\FR\FM\06MYN1.SGM
06MYN1
1219
1227
1233
1235
1237
1238
1245
1246
1248
1249
1258
1475
1478
1480
1503
1585
1590
1595
2010
2565
2572
6250
7008
7010
7011
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
]]>Agencies
[Federal Register Volume 89, Number 88 (Monday, May 6, 2024)]
[Notices]
[Pages 37251-37252]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-09783]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1349]
Bulk Manufacturer of Controlled Substances Application: Research
Triangle Institute
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Research Triangle Institute has applied to be registered as a
bulk manufacturer of basic class(es) of controlled substance(s). Refer
to Supplementary Information listed below for further drug information.
[[Page 37252]]
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
July 5, 2024. Such persons may also file a written request for a
hearing on the application on or before July 5, 2024.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on March 11, 2024, Research Triangle Institute, 3040
East Cornwallis Road, Hermann Building, Room 106, Research Triangle
Park, North Carolina 27709-2194, applied to be registered as a bulk
manufacturer of the following basic class(es) of controlled
substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols.................. 7370 I
------------------------------------------------------------------------
The company plans to bulk manufacture the listed controlled
substance synthetically for distribution to its customers for research
and as analytical reference standards. No other activities for this
drug code are authorized for this registration.
Marsha Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024-09783 Filed 5-3-24; 8:45 am]
BILLING CODE P
